| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 52 | 2021 | 2887 | 2.640 |
Why?
|
| Prostatic Neoplasms | 21 | 2023 | 1720 | 2.190 |
Why?
|
| Antineoplastic Agents, Hormonal | 17 | 2018 | 150 | 2.110 |
Why?
|
| Neoplasm Recurrence, Local | 22 | 2023 | 1313 | 1.790 |
Why?
|
| Tamoxifen | 20 | 2014 | 168 | 1.680 |
Why?
|
| Androgen Antagonists | 9 | 2023 | 144 | 1.290 |
Why?
|
| Proportional Hazards Models | 19 | 2017 | 857 | 1.280 |
Why?
|
| Randomized Controlled Trials as Topic | 21 | 2020 | 864 | 1.180 |
Why?
|
| Research Design | 8 | 2020 | 594 | 1.140 |
Why?
|
| Neoplasms | 14 | 2021 | 2897 | 1.100 |
Why?
|
| Data Interpretation, Statistical | 8 | 2021 | 297 | 1.100 |
Why?
|
| Clinical Trials, Phase III as Topic | 6 | 2016 | 172 | 1.050 |
Why?
|
| Statistics as Topic | 2 | 2021 | 238 | 1.030 |
Why?
|
| Obesity | 6 | 2021 | 963 | 0.830 |
Why?
|
| Models, Statistical | 6 | 2017 | 574 | 0.820 |
Why?
|
| Biomarkers, Tumor | 11 | 2019 | 1464 | 0.800 |
Why?
|
| Receptors, Estrogen | 17 | 2012 | 384 | 0.800 |
Why?
|
| Disease-Free Survival | 28 | 2019 | 1204 | 0.780 |
Why?
|
| Prostate-Specific Antigen | 8 | 2023 | 352 | 0.750 |
Why?
|
| Antineoplastic Agents | 13 | 2021 | 2357 | 0.740 |
Why?
|
| Survival Analysis | 20 | 2017 | 1538 | 0.700 |
Why?
|
| Brain Neoplasms | 7 | 2017 | 763 | 0.700 |
Why?
|
| Humans | 117 | 2023 | 86601 | 0.690 |
Why?
|
| Biomarkers | 3 | 2021 | 1718 | 0.680 |
Why?
|
| Clinical Trials as Topic | 11 | 2020 | 1169 | 0.650 |
Why?
|
| Middle Aged | 69 | 2021 | 25017 | 0.620 |
Why?
|
| Aged | 54 | 2022 | 18402 | 0.600 |
Why?
|
| Medical Futility | 1 | 2016 | 28 | 0.570 |
Why?
|
| Female | 74 | 2022 | 44507 | 0.550 |
Why?
|
| Chemotherapy, Adjuvant | 14 | 2011 | 468 | 0.550 |
Why?
|
| Prognosis | 24 | 2014 | 3674 | 0.530 |
Why?
|
| Colonic Neoplasms | 6 | 2016 | 556 | 0.520 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2015 | 155 | 0.510 |
Why?
|
| Risk Assessment | 13 | 2020 | 2261 | 0.510 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 270 | 0.490 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2014 | 2436 | 0.470 |
Why?
|
| Radiation Oncology | 2 | 2016 | 119 | 0.470 |
Why?
|
| Neoplasm Staging | 19 | 2018 | 1937 | 0.470 |
Why?
|
| Odds Ratio | 11 | 2020 | 678 | 0.460 |
Why?
|
| Disease Progression | 10 | 2020 | 1531 | 0.460 |
Why?
|
| Glioblastoma | 4 | 2017 | 255 | 0.450 |
Why?
|
| Male | 45 | 2023 | 40956 | 0.440 |
Why?
|
| Body Mass Index | 5 | 2013 | 770 | 0.430 |
Why?
|
| Likelihood Functions | 3 | 2014 | 251 | 0.430 |
Why?
|
| Clinical Trials Data Monitoring Committees | 2 | 2016 | 6 | 0.420 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2018 | 860 | 0.410 |
Why?
|
| Lymph Nodes | 4 | 2012 | 530 | 0.400 |
Why?
|
| Survival Rate | 17 | 2017 | 1860 | 0.400 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1961 | 0.380 |
Why?
|
| Treatment Outcome | 23 | 2020 | 7988 | 0.380 |
Why?
|
| Biometry | 3 | 2011 | 66 | 0.370 |
Why?
|
| Aged, 80 and over | 20 | 2020 | 6501 | 0.360 |
Why?
|
| Patient Compliance | 1 | 2011 | 227 | 0.360 |
Why?
|
| Neoplasms, Second Primary | 5 | 2006 | 252 | 0.350 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2011 | 487 | 0.350 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2020 | 166 | 0.350 |
Why?
|
| Cognition Disorders | 1 | 2011 | 236 | 0.340 |
Why?
|
| Adult | 34 | 2020 | 25640 | 0.340 |
Why?
|
| Estrogen Antagonists | 5 | 2004 | 48 | 0.340 |
Why?
|
| Follow-Up Studies | 16 | 2022 | 3636 | 0.340 |
Why?
|
| Lymphatic Metastasis | 11 | 2012 | 481 | 0.340 |
Why?
|
| Health Status Disparities | 2 | 2011 | 170 | 0.330 |
Why?
|
| Multicenter Studies as Topic | 6 | 2012 | 159 | 0.320 |
Why?
|
| Salvage Therapy | 2 | 2020 | 233 | 0.310 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2018 | 118 | 0.300 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 6 | 2011 | 111 | 0.290 |
Why?
|
| Pleural Neoplasms | 3 | 2013 | 188 | 0.290 |
Why?
|
| United States | 18 | 2019 | 6665 | 0.290 |
Why?
|
| Health Services Accessibility | 4 | 2021 | 394 | 0.290 |
Why?
|
| Mesothelioma | 4 | 2013 | 311 | 0.280 |
Why?
|
| Risk Factors | 14 | 2020 | 5416 | 0.270 |
Why?
|
| Cause of Death | 3 | 2019 | 277 | 0.270 |
Why?
|
| Mastectomy, Segmental | 8 | 2011 | 92 | 0.270 |
Why?
|
| Genes, BRCA1 | 4 | 2008 | 192 | 0.260 |
Why?
|
| Quality of Life | 5 | 2022 | 1583 | 0.260 |
Why?
|
| Endpoint Determination | 3 | 2020 | 60 | 0.250 |
Why?
|
| Drug Administration Schedule | 5 | 2018 | 916 | 0.250 |
Why?
|
| Estrogen Receptor Modulators | 2 | 2003 | 10 | 0.250 |
Why?
|
| Prostatectomy | 4 | 2022 | 471 | 0.250 |
Why?
|
| Incidence | 6 | 2022 | 1576 | 0.240 |
Why?
|
| Tosyl Compounds | 3 | 2021 | 15 | 0.230 |
Why?
|
| Medical Oncology | 2 | 2004 | 359 | 0.230 |
Why?
|
| Radiotherapy | 6 | 2017 | 328 | 0.230 |
Why?
|
| Mass Screening | 4 | 2019 | 617 | 0.230 |
Why?
|
| Combined Modality Therapy | 12 | 2017 | 1685 | 0.230 |
Why?
|
| Anilides | 3 | 2021 | 47 | 0.230 |
Why?
|
| Nitriles | 3 | 2021 | 149 | 0.220 |
Why?
|
| Radiation Pneumonitis | 1 | 2022 | 21 | 0.220 |
Why?
|
| Dacarbazine | 4 | 2017 | 102 | 0.210 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2002 | 156 | 0.210 |
Why?
|
| Neoplasm Metastasis | 8 | 2021 | 1056 | 0.210 |
Why?
|
| Rectal Neoplasms | 1 | 2003 | 116 | 0.210 |
Why?
|
| Social Class | 2 | 2016 | 127 | 0.200 |
Why?
|
| Lung Neoplasms | 4 | 2022 | 2261 | 0.190 |
Why?
|
| Electronic Mail | 1 | 2020 | 14 | 0.190 |
Why?
|
| Radiotherapy Dosage | 3 | 2019 | 468 | 0.190 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2017 | 138 | 0.190 |
Why?
|
| Pneumonia | 1 | 2022 | 179 | 0.190 |
Why?
|
| Coronavirus | 1 | 2020 | 19 | 0.190 |
Why?
|
| Kallikreins | 1 | 2020 | 47 | 0.190 |
Why?
|
| Hypersensitivity | 1 | 2022 | 154 | 0.190 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2012 | 176 | 0.180 |
Why?
|
| Treatment Failure | 4 | 2017 | 285 | 0.180 |
Why?
|
| Time Factors | 12 | 2020 | 5209 | 0.180 |
Why?
|
| Neoplasm Grading | 6 | 2021 | 357 | 0.180 |
Why?
|
| Confidence Intervals | 2 | 2014 | 229 | 0.180 |
Why?
|
| Biomedical Research | 1 | 2004 | 375 | 0.180 |
Why?
|
| Head and Neck Neoplasms | 4 | 2011 | 1052 | 0.170 |
Why?
|
| Double-Blind Method | 9 | 2020 | 1823 | 0.170 |
Why?
|
| Educational Status | 3 | 2020 | 188 | 0.170 |
Why?
|
| Breast | 3 | 2013 | 286 | 0.170 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2019 | 33 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2018 | 1075 | 0.170 |
Why?
|
| Risk | 5 | 2019 | 674 | 0.170 |
Why?
|
| Radiosurgery | 1 | 2022 | 272 | 0.170 |
Why?
|
| Tobacco Smoking | 1 | 2018 | 25 | 0.170 |
Why?
|
| Papillomavirus Infections | 2 | 2018 | 239 | 0.170 |
Why?
|
| DNA Mismatch Repair | 1 | 2019 | 52 | 0.170 |
Why?
|
| Cisplatin | 2 | 2018 | 612 | 0.160 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2012 | 381 | 0.160 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2019 | 42 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 104 | 0.160 |
Why?
|
| Cetuximab | 1 | 2018 | 113 | 0.160 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 370 | 0.160 |
Why?
|
| Patient Participation | 1 | 2020 | 216 | 0.160 |
Why?
|
| Computer Simulation | 4 | 2014 | 1078 | 0.160 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2019 | 137 | 0.160 |
Why?
|
| Prospective Studies | 7 | 2022 | 4210 | 0.160 |
Why?
|
| Receptors, Progesterone | 5 | 2012 | 167 | 0.150 |
Why?
|
| Life Expectancy | 2 | 2009 | 86 | 0.150 |
Why?
|
| SEER Program | 3 | 2019 | 184 | 0.150 |
Why?
|
| Socioeconomic Factors | 4 | 2010 | 567 | 0.150 |
Why?
|
| Electronic Health Records | 1 | 2020 | 319 | 0.150 |
Why?
|
| Genes, BRCA2 | 2 | 2008 | 160 | 0.140 |
Why?
|
| Internal-External Control | 1 | 2016 | 44 | 0.140 |
Why?
|
| Mammography | 4 | 2013 | 461 | 0.140 |
Why?
|
| Coronary Disease | 1 | 1997 | 261 | 0.140 |
Why?
|
| Religion | 1 | 2016 | 87 | 0.130 |
Why?
|
| Nomograms | 2 | 2012 | 28 | 0.130 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 1019 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 316 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 301 | 0.130 |
Why?
|
| Probability | 1 | 2016 | 355 | 0.130 |
Why?
|
| Epidemiologic Research Design | 1 | 2014 | 22 | 0.130 |
Why?
|
| Health Literacy | 1 | 2016 | 70 | 0.130 |
Why?
|
| Pandemics | 1 | 2020 | 740 | 0.120 |
Why?
|
| Regression Analysis | 2 | 2014 | 596 | 0.120 |
Why?
|
| Cohort Studies | 5 | 2022 | 2767 | 0.120 |
Why?
|
| Early Detection of Cancer | 2 | 2014 | 392 | 0.120 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2013 | 45 | 0.120 |
Why?
|
| ErbB Receptors | 3 | 2012 | 485 | 0.120 |
Why?
|
| alpha-Tocopherol | 1 | 2013 | 9 | 0.120 |
Why?
|
| Selenomethionine | 1 | 2013 | 11 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1074 | 0.110 |
Why?
|
| Quality Assurance, Health Care | 2 | 2012 | 220 | 0.110 |
Why?
|
| Cyclophosphamide | 4 | 2012 | 299 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2014 | 311 | 0.110 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 70 | 0.110 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2019 | 173 | 0.110 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2012 | 94 | 0.110 |
Why?
|
| Age Factors | 5 | 2020 | 1849 | 0.110 |
Why?
|
| Drug Design | 1 | 2012 | 124 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 2270 | 0.110 |
Why?
|
| Drug Dosage Calculations | 1 | 2012 | 16 | 0.110 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2012 | 24 | 0.110 |
Why?
|
| Arsenic Poisoning | 1 | 2013 | 103 | 0.110 |
Why?
|
| Antioxidants | 1 | 2013 | 223 | 0.100 |
Why?
|
| Body Weight | 3 | 2013 | 459 | 0.100 |
Why?
|
| DNA Methylation | 4 | 2015 | 628 | 0.100 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 1673 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 508 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2014 | 930 | 0.100 |
Why?
|
| Retrospective Studies | 6 | 2023 | 8475 | 0.100 |
Why?
|
| Stroke | 1 | 2000 | 965 | 0.100 |
Why?
|
| Doxorubicin | 2 | 2012 | 295 | 0.090 |
Why?
|
| Chemoradiotherapy | 3 | 2018 | 301 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 3 | 2008 | 552 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 1 | 2012 | 317 | 0.090 |
Why?
|
| Decision Making | 3 | 2016 | 642 | 0.090 |
Why?
|
| Death Certificates | 1 | 2009 | 11 | 0.090 |
Why?
|
| Registries | 2 | 2013 | 702 | 0.090 |
Why?
|
| Genes, erbB-2 | 1 | 2009 | 24 | 0.090 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2010 | 54 | 0.090 |
Why?
|
| Pneumonectomy | 1 | 2012 | 196 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 1169 | 0.090 |
Why?
|
| Neuropsychological Tests | 1 | 2011 | 502 | 0.090 |
Why?
|
| Germ-Line Mutation | 2 | 2019 | 329 | 0.080 |
Why?
|
| Quinazolines | 1 | 2010 | 220 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2009 | 219 | 0.080 |
Why?
|
| Time | 1 | 2008 | 77 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 541 | 0.080 |
Why?
|
| Fallopian Tubes | 1 | 2008 | 41 | 0.080 |
Why?
|
| Fanconi Anemia Complementation Group F Protein | 1 | 2007 | 6 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2012 | 428 | 0.080 |
Why?
|
| Ovariectomy | 1 | 2008 | 81 | 0.080 |
Why?
|
| Colorectal Neoplasms | 2 | 2006 | 938 | 0.080 |
Why?
|
| Mutation | 3 | 2008 | 3967 | 0.080 |
Why?
|
| Analysis of Variance | 2 | 2012 | 912 | 0.070 |
Why?
|
| Parent-Child Relations | 1 | 2007 | 77 | 0.070 |
Why?
|
| Disclosure | 1 | 2007 | 108 | 0.070 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2007 | 165 | 0.070 |
Why?
|
| Estrogen Receptor alpha | 1 | 2007 | 144 | 0.070 |
Why?
|
| Survival | 1 | 2006 | 21 | 0.070 |
Why?
|
| Vulnerable Populations | 1 | 2007 | 76 | 0.070 |
Why?
|
| Flutamide | 2 | 2017 | 4 | 0.070 |
Why?
|
| Goserelin | 2 | 2017 | 6 | 0.070 |
Why?
|
| Disability Evaluation | 1 | 2007 | 136 | 0.070 |
Why?
|
| Aneuploidy | 1 | 2005 | 55 | 0.070 |
Why?
|
| Proton Therapy | 2 | 2016 | 27 | 0.070 |
Why?
|
| Geriatric Assessment | 1 | 2007 | 166 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2005 | 110 | 0.070 |
Why?
|
| North America | 1 | 2005 | 180 | 0.070 |
Why?
|
| Bayes Theorem | 2 | 2014 | 361 | 0.060 |
Why?
|
| Growth Inhibitors | 1 | 2004 | 41 | 0.060 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2004 | 34 | 0.060 |
Why?
|
| Technology, Radiologic | 2 | 2016 | 103 | 0.060 |
Why?
|
| Cancer Care Facilities | 1 | 2003 | 28 | 0.060 |
Why?
|
| Logistic Models | 2 | 2020 | 1185 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 307 | 0.060 |
Why?
|
| Body Composition | 1 | 2003 | 68 | 0.060 |
Why?
|
| Travel | 1 | 2003 | 68 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2004 | 120 | 0.060 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2004 | 122 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2011 | 1565 | 0.060 |
Why?
|
| Interprofessional Relations | 1 | 2004 | 121 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2004 | 254 | 0.050 |
Why?
|
| Young Adult | 2 | 2012 | 5974 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2008 | 645 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2004 | 174 | 0.050 |
Why?
|
| Lomustine | 2 | 2012 | 26 | 0.050 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2012 | 70 | 0.050 |
Why?
|
| Neoplasms, Experimental | 1 | 2004 | 269 | 0.050 |
Why?
|
| Bevacizumab | 2 | 2014 | 281 | 0.050 |
Why?
|
| Consensus | 1 | 2004 | 335 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2004 | 444 | 0.050 |
Why?
|
| Hematuria | 1 | 2022 | 49 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2004 | 482 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2004 | 429 | 0.050 |
Why?
|
| Carcinoma in Situ | 2 | 1999 | 53 | 0.050 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2022 | 134 | 0.050 |
Why?
|
| Selection Bias | 1 | 2020 | 37 | 0.050 |
Why?
|
| Comorbidity | 1 | 2004 | 943 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 683 | 0.050 |
Why?
|
| Monte Carlo Method | 2 | 2014 | 185 | 0.050 |
Why?
|
| Symptom Assessment | 1 | 2020 | 65 | 0.050 |
Why?
|
| Multivariate Analysis | 3 | 2011 | 999 | 0.050 |
Why?
|
| Prostate | 1 | 2023 | 377 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 2501 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2019 | 26 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2020 | 364 | 0.040 |
Why?
|
| Patient Selection | 1 | 2003 | 685 | 0.040 |
Why?
|
| Receptor, ErbB-2 | 2 | 2012 | 223 | 0.040 |
Why?
|
| Contrast Media | 1 | 2004 | 1077 | 0.040 |
Why?
|
| Radiotherapy, Conformal | 1 | 2019 | 83 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2012 | 3241 | 0.040 |
Why?
|
| Mastectomy | 3 | 2012 | 236 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2022 | 408 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2013 | 2600 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 3 | 2007 | 937 | 0.040 |
Why?
|
| Bias | 2 | 2012 | 127 | 0.040 |
Why?
|
| China | 1 | 2019 | 228 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 1208 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 171 | 0.040 |
Why?
|
| Fluorouracil | 3 | 2011 | 556 | 0.040 |
Why?
|
| Cranial Irradiation | 1 | 2017 | 36 | 0.040 |
Why?
|
| Informed Consent | 1 | 2020 | 266 | 0.040 |
Why?
|
| Re-Irradiation | 1 | 2017 | 15 | 0.040 |
Why?
|
| Gynecomastia | 1 | 2017 | 8 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 258 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2022 | 629 | 0.040 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 71 | 0.040 |
Why?
|
| Canada | 2 | 2011 | 204 | 0.040 |
Why?
|
| Research Personnel | 1 | 2016 | 67 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2016 | 153 | 0.030 |
Why?
|
| Income | 1 | 2016 | 75 | 0.030 |
Why?
|
| Leucovorin | 2 | 2011 | 218 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 720 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 297 | 0.030 |
Why?
|
| DNA Modification Methylases | 1 | 2015 | 25 | 0.030 |
Why?
|
| Leuprolide | 1 | 2014 | 30 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2016 | 155 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2015 | 52 | 0.030 |
Why?
|
| Information Dissemination | 1 | 1995 | 103 | 0.030 |
Why?
|
| Urban Population | 1 | 2016 | 213 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 1239 | 0.030 |
Why?
|
| Social Support | 1 | 2016 | 193 | 0.030 |
Why?
|
| Markov Chains | 1 | 2014 | 125 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2014 | 138 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 1997 | 375 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 1998 | 636 | 0.030 |
Why?
|
| Lung Volume Measurements | 1 | 2013 | 19 | 0.030 |
Why?
|
| Cytostatic Agents | 1 | 2012 | 4 | 0.030 |
Why?
|
| Cytotoxins | 1 | 2012 | 15 | 0.030 |
Why?
|
| Postmenopause | 1 | 2013 | 98 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 279 | 0.030 |
Why?
|
| Ethics, Medical | 1 | 1995 | 306 | 0.030 |
Why?
|
| Pemetrexed | 1 | 2012 | 76 | 0.030 |
Why?
|
| Glutamates | 1 | 2012 | 89 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2012 | 40 | 0.030 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2012 | 63 | 0.030 |
Why?
|
| Credentialing | 1 | 2012 | 13 | 0.030 |
Why?
|
| Sample Size | 1 | 2012 | 130 | 0.030 |
Why?
|
| Bangladesh | 1 | 2013 | 318 | 0.030 |
Why?
|
| Body Surface Area | 1 | 2012 | 36 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2004 | 3352 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2005 | 451 | 0.030 |
Why?
|
| Taxoids | 1 | 2012 | 129 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2012 | 164 | 0.030 |
Why?
|
| Levamisole | 1 | 2011 | 5 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2012 | 91 | 0.030 |
Why?
|
| Guanine | 1 | 2012 | 208 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 303 | 0.030 |
Why?
|
| Vincristine | 1 | 2011 | 111 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2012 | 237 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2007 | 1990 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2012 | 170 | 0.020 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2011 | 19 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2011 | 124 | 0.020 |
Why?
|
| DNA Damage | 1 | 2012 | 366 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2005 | 236 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 266 | 0.020 |
Why?
|
| DNA Repair | 1 | 2012 | 356 | 0.020 |
Why?
|
| Glioma | 1 | 2012 | 285 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 291 | 0.020 |
Why?
|
| Senegal | 1 | 2009 | 4 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 429 | 0.020 |
Why?
|
| beta Catenin | 1 | 2011 | 251 | 0.020 |
Why?
|
| Nigeria | 1 | 2009 | 152 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2005 | 2426 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2005 | 1981 | 0.020 |
Why?
|
| Health Surveys | 1 | 2009 | 239 | 0.020 |
Why?
|
| Genetic Carrier Screening | 1 | 2008 | 60 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2012 | 434 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2705 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2008 | 98 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 1197 | 0.020 |
Why?
|
| CpG Islands | 1 | 2007 | 151 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1753 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 581 | 0.020 |
Why?
|
| Methotrexate | 2 | 1997 | 249 | 0.020 |
Why?
|
| Pedigree | 1 | 2008 | 966 | 0.020 |
Why?
|
| Data Collection | 1 | 2007 | 372 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 2232 | 0.020 |
Why?
|
| Adolescent | 2 | 2009 | 8979 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2007 | 204 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2005 | 49 | 0.020 |
Why?
|
| Models, Econometric | 1 | 2005 | 14 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 879 | 0.020 |
Why?
|
| Value of Life | 1 | 2005 | 22 | 0.020 |
Why?
|
| Stochastic Processes | 1 | 2005 | 74 | 0.020 |
Why?
|
| Azacitidine | 1 | 2005 | 137 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2005 | 207 | 0.020 |
Why?
|
| Minority Groups | 1 | 2006 | 137 | 0.020 |
Why?
|
| ROC Curve | 1 | 2007 | 752 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2004 | 153 | 0.020 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2004 | 19 | 0.020 |
Why?
|
| Interleukin-18 | 1 | 2004 | 26 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2007 | 839 | 0.020 |
Why?
|
| BRCA1 Protein | 1 | 2005 | 200 | 0.020 |
Why?
|
| Lymphopenia | 1 | 2004 | 28 | 0.020 |
Why?
|
| Receptors, Interferon | 1 | 2004 | 31 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2008 | 535 | 0.020 |
Why?
|
| STAT1 Transcription Factor | 1 | 2004 | 52 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2005 | 464 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 1804 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 2004 | 108 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2004 | 172 | 0.010 |
Why?
|
| Gadolinium DTPA | 1 | 2004 | 261 | 0.010 |
Why?
|
| Pyrroles | 1 | 2004 | 184 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2004 | 286 | 0.010 |
Why?
|
| Hospitals, University | 1 | 2003 | 194 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 348 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2006 | 380 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 302 | 0.010 |
Why?
|
| Indoles | 1 | 2004 | 318 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 696 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2004 | 267 | 0.010 |
Why?
|
| Cognition | 1 | 2007 | 570 | 0.010 |
Why?
|
| Transfection | 1 | 2004 | 896 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2004 | 790 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2007 | 1621 | 0.010 |
Why?
|
| Recurrence | 1 | 2004 | 1139 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2008 | 744 | 0.010 |
Why?
|
| Gene Expression | 1 | 2005 | 1284 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2004 | 449 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 2001 | 87 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2003 | 326 | 0.010 |
Why?
|
| Alleles | 1 | 2004 | 1127 | 0.010 |
Why?
|
| Melanoma | 1 | 2004 | 454 | 0.010 |
Why?
|
| Animals | 2 | 2012 | 26581 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2004 | 1924 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2004 | 724 | 0.010 |
Why?
|
| Liver | 1 | 2004 | 1229 | 0.010 |
Why?
|
| Necrosis | 1 | 1999 | 204 | 0.010 |
Why?
|
| Genotype | 1 | 2004 | 1850 | 0.010 |
Why?
|
| Chicago | 1 | 2003 | 1379 | 0.010 |
Why?
|
| Carcinoma, Lobular | 1 | 1999 | 80 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 1999 | 162 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2004 | 735 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2004 | 1195 | 0.010 |
Why?
|
| Phenotype | 1 | 2004 | 2377 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2004 | 3092 | 0.010 |
Why?
|
| Child | 1 | 2007 | 6926 | 0.010 |
Why?
|
| Federal Government | 1 | 1995 | 29 | 0.010 |
Why?
|
| Government Regulation | 1 | 1995 | 49 | 0.010 |
Why?
|
| Endometrial Neoplasms | 1 | 1996 | 193 | 0.010 |
Why?
|
| Mice | 1 | 2004 | 11352 | 0.010 |
Why?
|